We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

NHLBI Expands Their MetaCore™ License

Read time: 1 minute

GeneGo, Inc. has announced that their multi year agreement with NHLBI will be extended and expanded to cover National Heart, Lung and Blood Institute core microarray group, the Center for Information Technology and the Critical Care Medicine Department of the NIH Clinical Center

MetaCore™ will also be used throughout their systems biology group and it will be an integral part of their development.

The NHLBI Microarray Core supports NHLBI investigators conducting research with the goal of understanding the pathophysiology of human diseases employing high throughput technologies.

The large amount of data generated from such experimentation requires complex analytical tools for efficient data capture, analysis and interpretation of results.

As a central part of its role, the core provides computational and research tools to investigators in NHLBI, CIT and CCMD and helps them expand their ability to conduct genomic research through techniques mapping gene expression data to metabolic and signaling pathways.

Currently investigators sift through large gene lists trying to decipher which pathways are affected.

GeneGo’s MetaCore™ data mining software will provide factual, statistical, visual and machine learning techniques to rationalize the extensive changes in gene expression due to experimental conditions or disease processes, and DNA sequence variations.

There are currently fifty projects in the core using Affymetrix technology that will be directly improved by access to this software.

It is hoped that the application of the MetaCore™ analysis program would help decipher the key molecular mechanisms of disease progression, and offer diagnostic and therapeutic strategies for the future advancement of molecular-based medicines.

"We have enjoyed working with NHLBI over the years and we look forward to further expand these relationships with a larger group at the center," said Julie Bryant, Vice President of Business Development at GeneGo.

"The field of functional data mining is evolving very rapidly, and collaborations with the leading academic institutions help us to be on top of state of art technology."

"MetaCore™ is a very dynamic platform, and the feedback from collaborators is essential in its development."

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.